|
Market Closed -
Nasdaq Stockholm
12:00:00 2026-10-20 EDT
|
5-day change | 1st Jan Change | ||
| 8.500 SEK | +4.42% |
|
+2.16% | -57.07% |
| 09-25 | 12 stocks have hit new 52-week lows on the Stockholm Stock Exchange so far today | FW |
| 09-22 | 16 stocks have so far today hit new 52-week lows on the Stockholm Stock Exchange | FW |
Company Valuation: Annexin Pharmaceuticals AB
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 137.2 | 154.2 | 88.39 | 230.8 | 139.8 | 70.97 | - |
| Change | - | 12.35% | -42.68% | 161.1% | -39.44% | -49.23% | - |
| Enterprise Value (EV) | 137.2 | 154.2 | 66.97 | 214.4 | 139.8 | 70.97 | 70.97 |
| Change | - | 12.35% | -56.57% | 220.2% | -34.82% | -49.23% | 0% |
| P/E | - | - | - | - | - | - | - |
| PBR | - | - | - | - | - | - | - |
| PEG | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | 1.53x | 2.14x |
| EV / Revenue | - | - | - | - | - | 1.53x | 2.14x |
| EV / EBITDA | - | -0x | - | -0x | -0x | -6.17x | -2.85x |
| EV / EBIT | - | -0x | -0x | -0x | -0x | -6.17x | -2.85x |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | - | - | - | - | - | - | - |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | 46.3 | 33.1 |
| EBITDA 1 | - | -40.53 | - | -50.48 | -37.36 | -11.5 | -24.9 |
| EBIT 1 | - | -40.72 | -44.18 | -50.48 | -37.36 | -11.5 | -24.9 |
| Net income 1 | -52.14 | -40.73 | -44.05 | -50.25 | -36.89 | -11.5 | -24.9 |
| Net Debt | - | - | -21.42 | -16.34 | - | - | - |
| Reference price 2 | 100.000 | 99.800 | 26.000 | 43.300 | 19.800 | 8.140 | 8.140 |
| Nbr of stocks (in thousands) | 1,372 | 1,545 | 3,399 | 5,330 | 7,059 | 8,718 | - |
| Announcement Date | 2/3/22 | 2/7/23 | 2/9/24 | 2/6/25 | 2/5/26 | - | - |
1SEK in Million2
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 7.17M | |
| 19.06x | 6.78x | 13.59x | 1.56% | 65.83B | |
| 35.71x | 6.35x | 18.96x | 0.91% | 51.87B | |
| 27.56x | 7.53x | 23.84x | 0.05% | 51.2B | |
| 33.88x | 3.31x | 14.28x | -.--% | 43.76B | |
| 48.73x | 5.61x | 30.83x | -.--% | 42.09B | |
| -18.92x | 193.08x | -20x | -.--% | 39.04B | |
| 29.6x | 8.38x | 21.69x | 0.36% | 34B | |
| 29.17x | 6.17x | 16.01x | -.--% | 25.2B | |
| 31.2x | 5.77x | 19.4x | -.--% | 22.8B | |
| Average | 26.22x | 27.00x | 15.40x | 0.32% | 37.58B | |
| Weighted average by Cap. | 25.99x | 25.69x | 15.50x | 0.44% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ANNX Stock
- Valuation Annexin Pharmaceuticals AB
Select your edition
All financial news and data tailored to specific country editions
